Table 2 Management of osteoporosis risk from randomization date until 6 months after enrolment
From: Community based intervention to optimize osteoporosis management: randomized controlled trial
N= 201 | ||||
|---|---|---|---|---|
Variable, n(%) | IP (n= 101) | DP (n= 100) | RR (95% CI of RR) | DP 6-12 months* (n= 100) |
Appropriate osteoporosis risk management | ||||
Use of alendronate, risedronate, raloxifene with BMD result of t ≤ -2.5 (osteoporosis) | 29/52 (55.8%) | 16/60 (26.7%) | 2.09 (1.29,3.40) | 33/60 (55.0%) |
Use of alendronate, risedronate, raloxifene with BMD result of -2.5 < t < -1 (osteopenia) | 16/39 (41.0%) | 5/31 (16.1%) | 2.54 (1.05,6.17) | 8/31 (25.8%) |
Recommended amount of calcium | 54/101 (53.5%) | 20/100 (20.0%) | 2.67 (1.74,4.12) | 46/100 (46.0%) |
Recommended Amount of vitamin D | 33/101 (32.7%) | 20/100 (20.0%) | 1.63 (1.01,2.65) | 36/100 (36.0%) |
Estrogen or progestin | 13/101 (12.9%) | 2/100 (2.00%) | 6.44 (1.49,27.8) | 6/100 (6.00%) |
Health Status | ||||
Mean OPTQoL score ± SD at baseline | 205 ± 58 | 212 ± 54 | N/A | |
Mean OPTQoL score ± SD after 6 mos. of intervention | 207 ± 55 | 220 ± 50 | ||
P-value of difference | 0.58 | 0.26 | ||